VSEVOLOD RUDOY: Open Payments
NPI 1619920113 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,051 in 59 payments from 16 companies in 2025. Trend: 2023 $2,072 · 2024 $1,264 · 2025 $2,051
Food & beverage: $2,051
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $460 |
| Janssen Pharmaceuticals, Inc | 5 | $316 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $302 |
| ABBVIE INC. | 7 | $274 |
| Lundbeck LLC | 7 | $176 |
| Corium, LLC | 5 | $127 |
| Bausch Health US, LLC | 4 | $81 |
| E.R. Squibb & Sons, L.L.C. | 4 | $76 |
| Neos Therapeutics, LP | 1 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $55 |
Products named: REXULTI, SPRAVATO, CAPLYTA, VRAYLAR, ABILIFY MAINTENA, Azstarys, APLENZIN, COBENFY.
Industry payments across NY — which companies pay providers there.
